Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. (2020)
Attributed to:
Predictive biomarkers of response to DNA repair targeting agents in sporadic prostate cancer
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/s1470-2045(19)30684-9
PubMed Identifier: 31806540
Publication URI: http://europepmc.org/abstract/MED/31806540
Type: Journal Article/Review
Volume: 21
Parent Publication: The Lancet. Oncology
Issue: 1
ISSN: 1470-2045